UNSPSC 51262505: Guanazodine sulfate

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H20N4.H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKI3DAO4S6. The term guanazodine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule guanazodine sulfate under HS 29339990 and SITC 51577. SMILES: C1CCCNC(CC1)CNC(=N)N.OS(=O)(=O)O.

UNSPSC 51262505 Guanazodine sulfate is a Commodity code for a specific pharmaceutical product, but the recent state and local procurement activity tagged under this code does not reflect guanazodine sulfate purchases. Instead, Seminole County, Florida solicited naloxone and drug deactivation systems—opioid overdose reversal medication and harm-reduction equipment—under IFB 60459723LAS in July 2023. The mismatch between the code's nominal scope and the actual work being bought suggests this Commodity code sees limited or misclassified state and local procurement activity aligned with its intended product category.

The single recent opportunity on record is Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement closed July 26, 2023, and required vendors to include all shipping and delivery costs, maintain drug-free workplace certification and E-Verify compliance, and carry workers' compensation, commercial general liability, and professional liability insurance. The contract offered an initial two-year term with a one-year renewal option and a three-month probationary period. No explicit set-aside designations were noted. Without additional recent opportunities under this code to establish geographic spread or issuing-body patterns, the available evidence suggests minimal current state and local procurement activity aligned with guanazodine sulfate itself.